Invention Grant
US08288087B2 Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma
失效
使用黑素瘤抑制活性(MIA)蛋白作为黑色素瘤治疗反应的早期指标
- Patent Title: Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma
- Patent Title (中): 使用黑素瘤抑制活性(MIA)蛋白作为黑色素瘤治疗反应的早期指标
-
Application No.: US12375074Application Date: 2007-07-26
-
Publication No.: US08288087B2Publication Date: 2012-10-16
- Inventor: Nguyen Tan , Eleni Venetsanakos , Michel Faure , Carla Heise
- Applicant: Nguyen Tan , Eleni Venetsanakos , Michel Faure , Carla Heise
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Foley & Lardner LLP
- International Application: PCT/US2007/016848 WO 20070726
- International Announcement: WO2008/013912 WO 20080131
- Main IPC: G01N33/48
- IPC: G01N33/48 ; G01N33/50 ; G01N33/53 ; G01N33/574

Abstract:
The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.
Public/Granted literature
Information query